Recent developments in renal cell cancer immunotherapy

Bibliography

• LIPWORTH L TR, MCLAUGHLIN JK: The epidemiology of renal cell carcinoma. J. Urol. (2006) 176:2353-2358.
   PubMed Web of Science ®Google Scholar
• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
   PubMed Web of Science ®Google Scholar
• RIES LA, EISNER M, KOSARY CL et al.: SEER Cancer Statistics Review, 1973-1999. In: SEER Cancer Statistics Review, 1973-1999. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (Eds), National Cancer Institute, Bethesda, MD, USA (2002).
   Google Scholar
• MATHEW A, DEVESA SS, FRAUMENI JF JR, CHOW WH: Global increases in kidney cancer incidence, 1973-1992. Eur. J. Cancer Prev. (2002) 11(2):171-178.
   PubMed Web of Science ®Google Scholar
• COHEN HT, MCGOVERN FJ: Renal-cell carcinoma. N. Engl. J. Med. (2005) 353(23):2477-2490.
   PubMed Web of Science ®Google Scholar
• COPPIN C, PORZSOLT F, AWA A et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (2005) (1):CD001425.
   Google Scholar
• AMIN MB, AMIN MB, TAMBOLI P et al.: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. (2002) 26(3):281-291.
   PubMed Web of Science ®Google Scholar
• BECK SD, PATEL MI, SNYDER ME et al.: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann. Surg. Oncol. (2004) 11(1):71-77.
   PubMed Web of Science ®Google Scholar
• LINEHAN W: Genetic Basis of Renal Cell Carcinoma: Disease-Specific Approaches to Therapy. Linehan W (Ed.), (2005):362-367.
   Google Scholar
• ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124.
   PubMed Web of Science ®Google Scholar
• COLEY W: The treatment of malignant inoperable tumors with the mixed toxins of Erysipelas and Bacillus prodigiosus. Weissenbruch, Brussels, Belgium (1914).
   Google Scholar
• SNOW RM, SCHELLHAMMER PF: Spontaneous regression of metastatic renal cell carcinoma. Urology (1982) 20(2):177-181.
   PubMed Web of Science ®Google Scholar
• MONTIE JE, STEWART BH, STRAFFON RA et al.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol. (1977) 117(3):272-275.
   PubMed Web of Science ®Google Scholar
• GLEAVE ME, ELHILALI M, FRADET Y et al.: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N. Engl. J. Med. (1998) 338(18):1265-1271.
   PubMed Web of Science ®Google Scholar
• OLIVER RT, NETHERSELL AB, BOTTOMLEY JM: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br. J. Urol. (1989) 63(2):128-131.
   PubMedGoogle Scholar
• FLANIGAN RC, SALMON SE, BLUMENSTEIN BA et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. (2001) 345(23):1655-1659.
   PubMed Web of Science ®Google Scholar
• MICKISCH GH, GARIN A, VAN POPPEL H, DE PRIJCK L, SYLVESTER R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 358(9286):966-970.
   PubMed Web of Science ®Google Scholar
• DERWEESH IH, TANNENBAUM CS, RAYMAN PA, FINKE JH: Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat. Res. (2003) 116:29-51.
   PubMedGoogle Scholar
• FINKE JH, TUBBS R, CONNELLY B, PONTES E, MONTIE J: Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann. NY Acad. Sci. (1988) 532:387-394.
   PubMed Web of Science ®Google Scholar
• GABRILOVICH D, PISAREV V: Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets (2003) 4(7):525-536.
   PubMed Web of Science ®Google Scholar
• FISHMAN M, SEIGNE J: Immunotherapy of metastatic renal cell cancer. Cancer Control (2002) 9(4):293-304.
   PubMedGoogle Scholar
• MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N. Engl. J. Med. (1996) 335(12):865-875.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 353(9146):14-17.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, WEISS GR, MALIK UK et al.: The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J. Sci. Am. (1998) 4(3):162-167.
   PubMed Web of Science ®Google Scholar
• FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, FYFE G: High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J. Sci. Am. (1997) 3(Suppl. 1):S70-S72.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271(12):907-913.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. (1998) 228(3):307-319.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT DF, REGAN MM, CLARK JI et al.: Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2005) 23(1):133-141.
   PubMed Web of Science ®Google Scholar
• YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(16):3127-3132.
   PubMed Web of Science ®Google Scholar
• SAMLOWSKI WE, MCGREGOR JR, JUREK M et al.: ReGel polymer-based delivery of interleukin-2 as a cancer treatment. J. Immunother. (2006) 29(5):524-535.
   PubMed Web of Science ®Google Scholar
• TANNENBAUM CS, TUBBS R, ARMSTRONG D et al.: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. (1998) 161(2):927-932.
   PubMed Web of Science ®Google Scholar
• MULLINS IM, SLINGLUFF CL, LEE JK et al.: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. (2004) 64(21):7697-7701.
   PubMed Web of Science ®Google Scholar
• SHARMA S, STOLINA M, LUO J et al.: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. (2000) 164(9):4558-4563.
   PubMed Web of Science ®Google Scholar
• BURDICK MD, MURRAY LA, KEANE MP et al.: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am. J. Respir. Crit. Care Med. (2005) 171(3):261-268.
   PubMed Web of Science ®Google Scholar
• YANG J, RICHMOND A: The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. (2004) 9(6):846-855.
   PubMed Web of Science ®Google Scholar
• PAN J, BURDICK MD, BELPERIO JA et al.: CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J. Immunol. (2006) 176(3):1456-1464.
   PubMed Web of Science ®Google Scholar
• RYAN C, GOLDMAN B, LARA P et al.: Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG-412. ASCO Annual Meeting. GA, USA (2 – 6 June 2006) Abstract 4525.
   Google Scholar
• GOLLOB JA, RICHMOND T, JONES J et al.: Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients with metastatic renal cell cancer. ASCO Annual Meeting. GA, USA (2 – 6 June 2006) Abstract 4538.
   Google Scholar
• HUDES G, CARDUCCI M, TOMCZAK P et al.: A Phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatement of first-line, poor-risk patients with advanced renall cell carcinoma. ASCO Annual Meeting. GA, USA (2 – 6 June 2006) Abstract LBA4.
   Google Scholar
• AMATO RJ, MORGAN M, RAWAT A: Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer (2006) 106(7):1498-1506.
   PubMed Web of Science ®Google Scholar
• SAKAGUCHI S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. (2005) 6(4):345-352.
   PubMed Web of Science ®Google Scholar
• VON BOEHMER H: Mechanisms of suppression by suppressor T cells. Nat. Immunol. (2005) 6(4):338-344.
   PubMed Web of Science ®Google Scholar
• AHMADZADEH M, ROSENBERG SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2409-2414.
   PubMed Web of Science ®Google Scholar
• GIDRON A, EKLUND J, MORTONE B et al.: Treg depletion with denileukin difititox (DD) enhances lymphocytosis and eosinophilia in patients treated with high-dose IL-2 (HDIL-2) for metastatic renal cell Cancer (MRCC). ASCO Annual Meeting. GA, USA (2 – 6 June 2006) Abstract 14627.
   Google Scholar
• KUBLER H, VIEWEG J: Vaccines in renal cell carcinoma. Semin. Oncol. (2006) 33(5):614-624.
   PubMed Web of Science ®Google Scholar
• DILLMAN R, BARTH N, VANDERMOLEN L et al.: Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother. Radiopharm. (2004) 19(5):570-580.
   PubMed Web of Science ®Google Scholar
• MCCUNE CS, O’DONNELL RW, MARQUIS DM, SAHASRABUDHE DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. (1990) 32(1):62-66.
   PubMed Web of Science ®Google Scholar
• SCHWAAB T, HEANEY JA, SCHNED AR et al.: A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol. (2000) 163(4):1322-1327.
   PubMed Web of Science ®Google Scholar
• SCHWAAB T, TRETTER CP, GIBSON JJ et al.: Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J. Urol. (2004) 171(3):1036-1042.
   PubMed Web of Science ®Google Scholar
• ANTONIA SJ, SEIGNE J, DIAZ J et al.: Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. (2002) 167(5):1995-2000.
   PubMed Web of Science ®Google Scholar
• PIZZA G, DE VINCI C, LO CONTE G et al.: Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol. (Praha) (2004) 50(6):175-183.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, JAFFEE EM, WEBER CE et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. (1997) 57(8):1537-1546.
   PubMed Web of Science ®Google Scholar
• TANI K, AZUMA M, NAKAZAKI Y et al.: Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther. (2004) 10(4):799-816.
   PubMed Web of Science ®Google Scholar
• DANNULL J, SU Z, RIZZIERI D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. (2005) 115(12):3623-3633.
   PubMed Web of Science ®Google Scholar
• SU Z, DANNULL J, HEISER A et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. (2003) 63(9):2127-2133.
   PubMed Web of Science ®Google Scholar
• GITLITZ BJ, BELLDEGRUN AS, ZISMAN A et al.: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. (2003) 26(5):412-419.
   PubMed Web of Science ®Google Scholar
• HOLTL L, ZELLE-RIESER C, GANDER H et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. (2002) 8(11):3369-3376.
   PubMed Web of Science ®Google Scholar
• OOSTERWIJK-WAKKA JC, TIEMESSEN DM, BLEUMER I et al.: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase I study. J. Immunother. (2002) 25(6):500-508.
   PubMed Web of Science ®Google Scholar
• AVIGAN D, VASIR B, GONG J et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10(14):4699-4708.
   PubMed Web of Science ®Google Scholar
• BARBUTO JA, ENSINA LF, NEVES AR et al.: Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. (2004) 53(12):1111-1118.
   PubMed Web of Science ®Google Scholar
• MARTEN A, RENOTH S, HEINICKE T et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. (2003) 14(5):483-494.
   PubMed Web of Science ®Google Scholar
• MOON Y, CHO SG, LEE JW et al.: Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors. Cancer Biother. Radiopharm. (2006) 21(3):211-216.
   PubMed Web of Science ®Google Scholar
• JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599.
   PubMed Web of Science ®Google Scholar
• MOISEYENKO VM, DANILOV AO, BALDUEVA IA et al.: Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. Ann. Oncol. (2005) 16(1):162-168.
   PubMedGoogle Scholar
• WYSOCKI PJ, GRABARCZYK P, MACKIEWICZ-WYSOCKA M, KOWALCZYK DW, MACKIEWICZ A: Genetically modified dendritic cells-a new, promising cancer treatment strategy? Expert Opin. Biol. Ther. (2002) 2(8):835-845.
   PubMed Web of Science ®Google Scholar
• ARDAVIN C, AMIGORENA S, REIS E SOUSA C: Dendritic cells: immunobiology and cancer immunotherapy. Immunity (2004) 20(1):17-23.
   PubMedGoogle Scholar
• BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol. (2000) 18:767-811.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
   PubMed Web of Science ®Google Scholar
• GALLUCCI S, MATZINGER P: Danger signals: SOS to the immune system. Curr. Opin. Immunol. (2001) 13(1):114-119.
   PubMed Web of Science ®Google Scholar
• SWITAJ T, JALILI A, JAKUBOWSKA AB et al.: CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. (2004) 10(12 Pt 1):4165-4175.
   PubMed Web of Science ®Google Scholar
• CHAGNON F, TANGUAY S, OZDAL OL et al.: Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin. Cancer Res. (2005) 11(3):1302-1311.
   PubMed Web of Science ®Google Scholar
• WIMPISSINGER T, FELZMANN T, HUGEL H, FUNOVICS P, STACKL W: Treatment of advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic cells. ASCO Annual Meeting. GA, USA (2 – 6 June 2006) Abstract 14585.
   Google Scholar
• WIERECKY J, MULLER MR, WIRTHS S et al.: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. (2006) 66(11):5910-5918.
   PubMed Web of Science ®Google Scholar
• ASSIKI V, DALIANI D, PAGLIARO L et al.: Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:386.
   Google Scholar
• BLEUMER I, KNUTH A, OOSTERWIJK E et al.: A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer (2004) 90(5):985-990.
   PubMed Web of Science ®Google Scholar
• SHORTS L, WEISS JM, LEE JK et al.: Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J. Immunol. (2006) 176(11):6543-6552.
   PubMed Web of Science ®Google Scholar
• YANG J, BECK K, BLANSFIELD J et al.: Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). ASCO Annual Meeting. Orlando, FL, USA (13 – 17 May 2005). Abstract 2501.
   Google Scholar
• BECK KE, BLANSFIELD JA, TRAN KQ et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. (2006) 24(15):2283-2289.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. (1993) 85(8):622-632.
   PubMed Web of Science ®Google Scholar
• YANG JC, CHILDS R: Immunotherapy for renal cell cancer. J. Clin. Oncol. (2006) 24(35):5576-5583.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, TANAKA Y, YAGI J, TOMA H, UCHIYAMA T: Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. (2001) 50(3):115-124.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, TANAKA Y, YAGI J et al.: Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. (2006) 56(4):469-476.
   PubMed Web of Science ®Google Scholar
• LAMERS CH, WILLEMSEN RA, LUIDER BA, DEBETS R, BOLHUIS RL: Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. (2002) 9(7):613-623.
   PubMed Web of Science ®Google Scholar
• LAMERS CH, SLEIJFER S, VULTO AG et al.: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. (2006) 24(13):e20-e22.
   PubMedGoogle Scholar
• THOMAS ED, BLUME KG: Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. (1999) 5(6):341-346.
   PubMedGoogle Scholar
• KOLB HJ, MITTERMULLER J, CLEMM C et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76(12):2462-2465.
   PubMed Web of Science ®Google Scholar
• BARKHOLT L, BREGNI M, REMBERGER M et al.: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann. Oncol. (2006) 17(7):1134-1140.
   PubMed Web of Science ®Google Scholar
• RZEPECKI P, ZOLNIEREK J, SAROSIEK T, LANGIEWICZ P, SZCZYLIK C: Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma – single center experience. Neoplasma (2005) 52(3):238-242.
   PubMed Web of Science ®Google Scholar
• VIEWEG J, JACKSON A: Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin. Biol. Ther. (2004) 4(11):1791-1801.
   PubMed Web of Science ®Google Scholar
• WYSOCKI PJ, KARCZEWSKA-DZIONK A, MACKIEWICZ-WYSOCKA M, MACKIEWICZ A: Human cancer gene therapy with cytokine gene-modified cells. Expert Opin. Biol. Ther. (2004) 4(10):1595-1607.
   PubMed Web of Science ®Google Scholar
• WYSOCKI PJ, KWIATKOWSKA EP, KAZIMIERCZAK U et al.: Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin. Cancer Res. (2006) 12(13):4095-4102.
   PubMed Web of Science ®Google Scholar
• MICHAELIS LC, RATAIN MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat.Rev. Cancer (2006) 6(5):409-414.
   Google Scholar
• RATAIN MJ: Phase II oncology trials: let’s be positive. Clin. Cancer Res. (2005) 11(16):5661-5662.
   PubMed Web of Science ®Google Scholar
• RATAIN MJ, ECKHARDT SG: Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J. Clin. Oncol. (2004) 22(22):4442-4445.
   PubMed Web of Science ®Google Scholar
• MOCELLIN S, MANDRUZZATO S, BRONTE V, MARINCOLA FM: Cancer vaccines: pessimism in check. Nat. Med. (2004) 10(12):1278-1279; author reply 1279-1280.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295(21):2516-2524.
   PubMed Web of Science ®Google Scholar